These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19931821)

  • 1. New antibiotics: optimal use in current clinical practice.
    Karageorgopoulos DE; Falagas ME
    Int J Antimicrob Agents; 2009; 34 Suppl 4():S55-62. PubMed ID: 19931821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antibiotic agents for bloodstream infections.
    Vergidis PI; Falagas ME
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for multidrug-resistant bacteria.
    Giamarellou H
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):601-18. PubMed ID: 17009940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant pathogen-associated skin and skin-structure infections: antibiotic options.
    Curcio D
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1019-36. PubMed ID: 20818946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of multidrug resistance: the treatment of gram-negative rod infections.
    Levin AS; Oliveira MS
    Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New therapeutic options for the treatment of multiresistant bacteria in the ICU].
    Barcenilla Gaite F; Jover Saenz A; Vallverdú Vidal M; Castellana Perello D
    Rev Esp Quimioter; 2008; 21 Spec No 1():9-13. PubMed ID: 18752075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in antibacterial therapy against emerging bacterial pathogens.
    Pournaras S; Iosifidis E; Roilides E
    Semin Hematol; 2009 Jul; 46(3):198-211. PubMed ID: 19549574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with recently approved antibiotics.
    Paterson DL
    Curr Opin Pharmacol; 2006 Oct; 6(5):486-90. PubMed ID: 16904377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
    Pappas G; Ierodiakonou V; Falagas ME
    Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P; Finch R
    Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence and management of drug-resistant enterococcal infections.
    Arias CA; Murray BE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):637-55. PubMed ID: 18847403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.